$14.97
-1.01-6.32%
Last update: 12:15 PM
15 minutes delayed
Comments
Loading...
Tourmaline Bio
TRMLNASDAQ
want to know what
the Bulls & Bears Say?
Tourmaline Bio (NASDAQ:TRML) Stock, Analyst Ratings, Price Targets, Forecasts
Tourmaline Bio Inc has a consensus price target of $61.8 based on the ratings of 5 analysts. The high is $74 issued by Truist Securities on March 25, 2024. The low is $48 issued by HC Wainwright & Co. on May 14, 2024. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Truist Securities, and Jefferies on May 14, 2024, March 25, 2024, and March 20, 2024, respectively. With an average price target of $64.67 between HC Wainwright & Co., Truist Securities, and Jefferies, there's an implied 331.98% upside for Tourmaline Bio Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Truist Securities
Jefferies
Guggenheim
Piper Sandler
1calculated from analyst ratings
Analyst Ratings for Tourmaline Bio
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 05/14/2024 | Buy Now | 220.64% | HC Wainwright & Co. | Yi Chen | → $48 | Reiterates | Buy → Buy | Get Alert |
| 03/25/2024 | Buy Now | 394.32% | Truist Securities | Robyn Karnauskas | → $74 | Reiterates | Buy → Buy | Get Alert |
| 03/20/2024 | Buy Now | 380.96% | Jefferies | Roger Song | $41 → $72 | Maintains | Buy | Get Alert |
| 03/20/2024 | Buy Now | 220.64% | HC Wainwright & Co. | Yi Chen | $48 → $48 | Reiterates | Buy → Buy | Get Alert |
| 12/15/2023 | Buy Now | 173.88% | Jefferies | Roger Song | → $41 | Initiates | → Buy | Get Alert |
| 11/17/2023 | Buy Now | 187.24% | Truist Securities | Robyn Karnauskas | → $43 | Initiates | → Buy | Get Alert |
| 10/31/2023 | Buy Now | 234% | Guggenheim | Yatin Suneja | → $50 | Initiates | → Buy | Get Alert |
| 10/25/2023 | Buy Now | 334.2% | Piper Sandler | Yasmeen Rahimi | → $65 | Initiates | → Overweight | Get Alert |
FAQ
What is the target price for Tourmaline Bio (TRML) stock?
The latest price target for Tourmaline Bio (NASDAQ:TRML) was reported by HC Wainwright & Co. on May 14, 2024. The analyst firm set a price target for $48.00 expecting TRML to rise to within 12 months (a possible 220.64% upside). 8 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Tourmaline Bio (TRML)?
The latest analyst rating for Tourmaline Bio (NASDAQ:TRML) was provided by HC Wainwright & Co., and Tourmaline Bio reiterated their buy rating.
When was the last upgrade for Tourmaline Bio (TRML)?
There is no last upgrade for Tourmaline Bio
When was the last downgrade for Tourmaline Bio (TRML)?
There is no last downgrade for Tourmaline Bio.
When is the next analyst rating going to be posted or updated for Tourmaline Bio (TRML)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Tourmaline Bio, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Tourmaline Bio was filed on May 14, 2024 so you should expect the next rating to be made available sometime around May 14, 2025.
Is the Analyst Rating Tourmaline Bio (TRML) correct?
While ratings are subjective and will change, the latest Tourmaline Bio (TRML) rating was a reiterated with a price target of $48.00 to $48.00. The current price Tourmaline Bio (TRML) is trading at is $14.97, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.